Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo (N=351) | | Zanamivir (N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| BLOOD & LYMPHATIC : | | | | |
| Any event | 0 | | 1 | (<1%) |
| Purpura | 0 | | 1 | (<1%) |
| CARDIOVASCULAR : | | | | |
| Any event | 1 | (<1%) | 3 | (<1%) |
| Hypertension | 1 | (<1%) | 0 | |
| Biventricular Heart Failure | 0 | | 1 | (<1%) |
| Syncope | 0 | | 1 | (<1%) |
| Tachyarrhythmias | 0 | | 1 | (<1%) |
| DRUG INTERACTION OVERDOSE & TRAUMA : | | | | |
| Any event | 9 | (3%) | 6 | (2%) |
| Muscle Injuries | 3 | (<1%) | 1 | (<1%) |
| Postoperative Complications | 2 | (<1%) | 1 | (<1%) |
| Injuries | 1 | (<1%) | 2 | (<1%) |
| Fractures | 1 | (<1%) | 1 | (<1%) |
| Dislocations | 1 | (<1%) | 0 | |
| Soft Tissue Injuries | 1 | (<1%) | 0 | |
| Contusions & Hematomas | 0 | | 1 | (<1%) |
| EAR NOSE & THROAT : | | | | |
| Any event | 117 | (33%) | 88 | (26%) |
| Throat & Tonsil Discomfort & Pain | 73 | (21%) | 58 | (17%) |
| Nasal Signs & Symptoms | 66 | (19%) | 43 | (13%) |
| Ear Nose & Throat Infections | 6 | (2%) | 3 | (<1%) |
| Nasal Inflammation | 6 | (2%) | 2 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo (N=351) | | Zanamivir (N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| EAR NOSE & THROAT (continued) | | | | |
| Any event | 117 | (33%) | 88 | (26%) |
| Viral Ear Nose & Throat Infections | 4 | (1%) | 2 | (<1%) |
| Sinusitis | 3 | (<1%) | 2 | (<1%) |
| Throat & Tonsil Signs & Symptoms | 2 | (<1%) | 3 | (<1%) |
| Upper Respiratory Inflammation | 3 | (<1%) | 0 | |
| Pharyngitis | 2 | (<1%) | 0 | |
| Ear Nose & Throat Hemorrhage | 1 | (<1%) | 1 | (<1%) |
| Ear Nose & Throat Signs & Symptoms | 0 | | 2 | (<1%) |
| Nasal Sinus Disorders | 0 | | 2 | (<1%) |
| Allergic Rhinitis | 1 | (<1%) | 0 | |
| Ear Signs & Symptoms | 1 | (<1%) | 0 | |
| Otitis | 1 | (<1%) | 0 | |
| Vocal Cord Disorders | 0 | | 1 | (<1%) |
| ENDOCRINE & METABOLIC : | | | | |
| Any event | 20 | (6%) | 13 | (4%) |
| Feeding Problems | 19 | (5%) | 10 | (3%) |
| Hyperglycemia | 1 | (<1%) | 1 | (<1%) |
| Diabetes Mellitus | 0 | | 1 | (<1%) |
| Disorders Of Magnesium Metabolism | 0 | | 1 | (<1%) |
| Disorders Of Uric Acid Metabolism | 0 | | 1 | (<1%) |
| EYE : | | | | |
| Any event | 2 | (<1%) | 4 | (1%) |
| Eye Pain & Discomfort | 2 | (<1%) | 1 | (<1%) |
| Eye Redness | 1 | (<1%) | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo<br>(N=351) | | Zanamivir<br>(N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| EYE (continued) | | | | |
| Any event | 2 | (<1%) | 4 | (1%) |
| Eye Infections | 0 | | 1 | (<1%) |
| Eye Irritation & Itching | 0 | | 1 | (<1%) |
| Eye Signs & Symptoms | 0 | | 1 | (<1%) |
| Viral Eye Infections | 0 | | 1 | (<1%) |
| GASTROINTESTINAL : | | | | |
| Any event | 36 | (10%) | 19 | (6%) |
| Nausea & Vomiting | 13 | (4%) | 6 | (2%) |
| Diarrhea | 9 | (3%) | 4 | (1%) |
| Dyspeptic Symptoms | 3 | (<1%) | 3 | (<1%) |
| Abdominal Discomfort & Pain | 2 | (<1%) | 2 | (<1%) |
| Constipation | 2 | (<1%) | 1 | (<1%) |
| Gastrointestinal Signs & Symptoms | 2 | (<1%) | 1 | (<1%) |
| Hyposalivation | 2 | (<1%) | 1 | (<1%) |
| Dental Discomfort & Pain | 2 | (<1%) | 0 | |
| Gastroenteritis | 2 | (<1%) | 0 | |
| Viral Gastrointestinal Infections | 2 | (<1%) | 0 | |
| Gastrointestinal Discomfort & Pain | 1 | (<1%) | 1 | (<1%) |
| Gastrointestinal Infections | 1 | (<1%) | 1 | (<1%) |
| Dental & Gum Inflammation | 0 | | 2 | (<1%) |
| Inflammation Of Oral Mucosa | 1 | (<1%) | 0 | |
| Oral Discomfort & Pain | 1 | (<1%) | 0 | |
| Bacterial Gastrointestinal Infections | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo (N=351) | | Zanamivir (N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| HEPATOBILIARY TRACT & PANCREAS : | | | | |
| Any event | 0 | | 1 | (<1%) |
| Pancreatitis | 0 | | 1 | (<1%) |
| LOWER RESPIRATORY : | | | | |
| Any event | 85 | (24%) | 86 | (25%) |
| Cough | 63 | (18%) | 60 | (18%) |
| Viral Respiratory Infections | 19 | (5%) | 23 | (7%) |
| Bronchitis | 6 | (2%) | 2 | (<1%) |
| Asthma | 4 | (1%) | 1 | (<1%) |
| Lower Respiratory Signs & Symptoms | 3 | (<1%) | 2 | (<1%) |
| Sputum | 3 | (<1%) | 2 | (<1%) |
| Breathing Disorders | 3 | (<1%) | 1 | (<1%) |
| Pneumonia | 1 | (<1%) | 1 | (<1%) |
| Chronic Obstructive Airways Disease | 0 | | 2 | (<1%) |
| Allergic Lower Respiratory Disorders | 1 | (<1%) | 0 | |
| Lung Disorders | 1 | (<1%) | 0 | |
| Pulmonary Edema | 0 | | 1 | (<1%) |
| MUSCULOSKELETAL : | | | | |
| Any event | 54 | (15%) | 38 | (11%) |
| Muscle Pain | 29 | (8%) | 19 | (6%) |
| Musculoskeletal Pain | 21 | (6%) | 20 | (6%) |
| Arthralgia & Articular Rheumatism | 4 | (1%) | 0 | |
| Arthritis | 1 | (<1%) | 0 | |
| Muscle Cramps & Spasms | 1 | (<1%) | 0 | |
| Musculoskeletal Discomfort | 1 | (<1%) | 0 | |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo (N=351) | | Zanamivir (N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| MUSCULOSKELETAL (continued) | | | | |
| Any event | 54 | (15%) | 38 | (11%) |
| Joint Stiffness Tightness & Rigidity | 0 | | 1 | (<1%) |
| NEUROLOGY : | | | | |
| Any event | 110 | (31%) | 80 | (24%) |
| Headaches | 106 | (30%) | 77 | (23%) |
| Migraines | 2 | (<1%) | 3 | (<1%) |
| Dizziness | 3 | (<1%) | 1 | (<1%) |
| Sleep Disorders | 1 | (<1%) | 2 | (<1%) |
| Hypoesthesia | 1 | (<1%) | 0 | |
| NON-SITE SPECIFIC : | | | | |
| Any event | 62 | (18%) | 52 | (15%) |
| Malaise & Fatigue | 41 | (12%) | 28 | (8%) |
| Temperature Regulation Disturbances | 32 | (9%) | 31 | (9%) |
| Pain | 3 | (<1%) | 2 | (<1%) |
| Edema & Swelling | 2 | (<1%) | 0 | |
| Chest Symptoms | 1 | (<1%) | 1 | (<1%) |
| Fungal Infections | 1 | (<1%) | 0 | |
| Inflammation | 1 | (<1%) | 0 | |
| Allergies & Allergic Reactions | 0 | | 1 | (<1%) |
| Cramps | 0 | | 1 | (<1%) |
| Hot & Cold Sensations | 0 | | 1 | (<1%) |
| Non-Specific Conditions | 0 | | 1 | (<1%) |
| Strange Feelings | 0 | | 1 | (<1%) |
| Viral Infections | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo (N=351) | | Zanamivir (N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| PSYCHIATRY : | | | | |
| Any event | 2 | (<1%) | 3 | (<1%) |
| Anxiety | 1 | (<1%) | 0 | |
| Mood Elevations | 1 | (<1%) | 0 | |
| Agitation | 0 | | 1 | (<1%) |
| Depressive Disorders | 0 | | 1 | (<1%) |
| Mood Disorders | 0 | | 1 | (<1%) |
| REPRODUCTION : | | | | |
| Any event | 5 | (1%) | 7 | (2%) |
| Menstruation Symptoms | 4 | (1%) | 4 | (1%) |
| Cysts Lumps & Masses Of Female Reproductive Tract | 1 | (<1%) | 1 | (<1%) |
| Fungal Reproductive Infections | 0 | | 2 | (<1%) |
| SKIN : | | | | |
| Any event | 3 | (<1%) | 8 | (2%) |
| Skin Rashes | 2 | (<1%) | 2 | (<1%) |
| Urticaria | 1 | (<1%) | 2 | (<1%) |
| Acne & Folliculitis | 0 | | 2 | (<1%) |
| Skin Cysts Lumps & Masses | 0 | | 2 | (<1%) |
| Skin & Subcutaneous Operations | 1 | (<1%) | 0 | |
| Fungal Skin Infections | 0 | | 1 | (<1%) |
| UROLOGY : | | | | |
| Any event | 3 | (<1%) | 1 | (<1%) |
| Urinary Infections | 2 | (<1%) | 0 | |
| Dysuria | 1 | (<1%) | 0 | |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.55
Summary of All Adverse Events

During Prophylaxis: Smokers

| BODY SYSTEM<br>Event | Placebo (N=351) | | Zanamivir (N=340) | |
|---|---|---|---|---|
| ANY EVENT | 202 | (58%) | 184 | (54%) |
| UROLOGY (continued) | | | | |
| Any event | 3 | (<1%) | 1 | (<1%) |
| Urinary Calculi | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| BLOOD & LYMPHATIC : | | | | |
| Any event | 4 | (<1%) | 6 | (<1%) |
| Lymphatic Signs & Symptoms | 3 | (<1%) | 4 | (<1%) |
| Abnormal White Cells & Counts | 1 | (<1%) | 0 | |
| Anemia | 0 | | 1 | (<1%) |
| Deficiency Anemia | 0 | | 1 | (<1%) |
| CARDIOVASCULAR : | | | | |
| Any event | 27 | (<1%) | 36 | (1%) |
| Hypertension | 9 | (<1%) | 5 | (<1%) |
| Flushing | 2 | (<1%) | 6 | (<1%) |
| Increased Blood Pressure | 2 | (<1%) | 4 | (<1%) |
| Tachyarrhythmias | 4 | (<1%) | 1 | (<1%) |
| Arrhythmias | 2 | (<1%) | 2 | (<1%) |
| Biventricular Heart Failure | 2 | (<1%) | 2 | (<1%) |
| Palpitations | 2 | (<1%) | 2 | (<1%) |
| Angina Pectoris | 1 | (<1%) | 3 | (<1%) |
| Syncope | 0 | | 4 | (<1%) |
| Cardiac Failure | 0 | | 2 | (<1%) |
| Cerebrovascular Accidents | 1 | (<1%) | 0 | |
| Coronary Artery Disorders | 1 | (<1%) | 0 | |
| Vasculitis | 1 | (<1%) | 0 | |
| Cardiovascular Symptoms | 0 | | 1 | (<1%) |
| Decreased Blood Pressure | 0 | | 1 | (<1%) |
| Extrasystoles | 0 | | 1 | (<1%) |
| Thrombophlebitis | 0 | | 1 | (<1%) |
| Vascular Disorders | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| DRUG INTERACTION OVERDOSE & TRAUMA : | | | | |
| Any event | 42 | (1%) | 41 | (1%) |
| Muscle Injuries | 8 | (<1%) | 11 | (<1%) |
| Fractures | 7 | (<1%) | 5 | (<1%) |
| Injuries | 5 | (<1%) | 7 | (<1%) |
| Contusions & Hematomas | 4 | (<1%) | 7 | (<1%) |
| Wounds & Lacerations | 8 | (<1%) | 0 | |
| Postoperative Complications | 2 | (<1%) | 4 | (<1%) |
| Complications Of Procedures | 3 | (<1%) | 2 | (<1%) |
| Ligament Tendon Or Cartilage Injuries | 2 | (<1%) | 1 | (<1%) |
| Soft Tissue Injuries | 2 | (<1%) | 1 | (<1%) |
| Burns | 1 | (<1%) | 1 | (<1%) |
| Injection Site Or Infusion Reactions | 0 | | 2 | (<1%) |
| Accidents | 1 | (<1%) | 0 | |
| Poisoning & Toxicity | 1 | (<1%) | 0 | |
| Complications Of Medical Care | 0 | | 1 | (<1%) |
| Craniocerebral Injuries | 0 | | 1 | (<1%) |
| Foreign Bodies | 0 | | 1 | (<1%) |
| EAR NOSE & THROAT : | | | | |
| Any event | 801 | (27%) | 753 | (25%) |
| Throat & Tonsil Discomfort & Pain | 465 | (16%) | 450 | (15%) |
| Nasal Signs & Symptoms | 350 | (12%) | 359 | (12%) |
| Ear Nose & Throat Infections | 52 | (2%) | 48 | (2%) |
| Sinusitis | 34 | (1%) | 32 | (1%) |
| Viral Ear Nose & Throat Infections | 29 | (<1%) | 24 | (<1%) |
| Ear Signs & Symptoms | 17 | (<1%) | 21 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| EAR NOSE & THROAT (continued) | | | | |
| Any event | 801 | (27%) | 753 | (25%) |
| Nasal Inflammation | 20 | (<1%) | 15 | (<1%) |
| Upper Respiratory Inflammation | 18 | (<1%) | 10 | (<1%) |
| Nasal Sinus Disorders | 15 | (<1%) | 10 | (<1%) |
| Pharyngitis | 10 | (<1%) | 10 | (<1%) |
| Ear Nose & Throat Hemorrhage | 12 | (<1%) | 6 | (<1%) |
| Throat & Tonsil Signs & Symptoms | 11 | (<1%) | 7 | (<1%) |
| Bacterial Ear Nose & Throat Infections | 10 | (<1%) | 5 | (<1%) |
| Laryngitis | 7 | (<1%) | 7 | (<1%) |
| Allergic Rhinitis | 11 | (<1%) | 2 | (<1%) |
| Vocal Cord Disorders | 3 | (<1%) | 6 | (<1%) |
| Ear Nose & Throat Signs & Symptoms | 1 | (<1%) | 2 | (<1%) |
| Tinnitus | 1 | (<1%) | 2 | (<1%) |
| Ear Nose & Throat Polyps | 2 | (<1%) | 0 | |
| Tympanum Disorders | 1 | (<1%) | 1 | (<1%) |
| Fungal Ear Nose & Throat Infections | 0 | | 2 | (<1%) |
| Otitis | 0 | | 2 | (<1%) |
| External Otitis | 1 | (<1%) | 0 | |
| Hearing Difficulty | 1 | (<1%) | 0 | |
| Hearing Loss | 1 | (<1%) | 0 | |
| Larynx Disorders | 1 | (<1%) | 0 | |
| Throat & Tonsil Edema & Swelling | 1 | (<1%) | 0 | |
| Ear Nose & Throat Disorders | 0 | | 1 | (<1%) |
| Operations On Middle Ear | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| ENDOCRINE & METABOLIC : | | | | |
| Any event | 113 | (4%) | 107 | (4%) |
| Feeding Problems | 103 | (3%) | 94 | (3%) |
| Hyperglycemia | 4 | (<1%) | 3 | (<1%) |
| Fluid Disturbances | 3 | (<1%) | 2 | (<1%) |
| Hypoglycemia | 3 | (<1%) | 1 | (<1%) |
| Disorders Of Uric Acid Metabolism | 2 | (<1%) | 1 | (<1%) |
| Disorders Of Thirst/Fluid Intake | 1 | (<1%) | 2 | (<1%) |
| Disorders Of Protein Metabolism | 1 | (<1%) | 0 | |
| Hypothyroidism | 1 | (<1%) | 0 | |
| Disorders Of Calcium & Phosphate Metabolism | 0 | | 1 | (<1%) |
| Disorders Of Carbohydrate Metabolism | 0 | | 1 | (<1%) |
| Goiter | 0 | | 1 | (<1%) |
| Weight Problems | 0 | | 1 | (<1%) |
| EYE : | | | | |
| Any event | 36 | (1%) | 23 | (<1%) |
| Eye Pain & Discomfort | 16 | (<1%) | 11 | (<1%) |
| Eye Redness | 13 | (<1%) | 9 | (<1%) |
| Keratitis & Conjunctivitis | 5 | (<1%) | 2 | (<1%) |
| Eye Infections | 3 | (<1%) | 3 | (<1%) |
| Eye Irritation & Itching | 3 | (<1%) | 2 | (<1%) |
| Lacrimal Disorders | 2 | (<1%) | 1 | (<1%) |
| Blindness & Low Vision | 1 | (<1%) | 0 | |
| Eye Hemorrhage | 1 | (<1%) | 0 | |
| Iritis & Iridocyclitis | 1 | (<1%) | 0 | |
| Light Sensitivity Of Eyes | 1 | (<1%) | 0 | |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| EYE (continued) | | | | |
| Any event | 36 | (1%) | 23 | (<1%) |
| Retinopathies | 1 | (<1%) | 0 | |
| Visual Field Defects | 1 | (<1%) | 0 | |
| Dry Eyes | 0 | | 1 | (<1%) |
| Ocular Pressure Disorders | 0 | | 1 | (<1%) |
| Visual Disturbances | 0 | | 1 | (<1%) |
| GASTROINTESTINAL : | | | | |
| Any event | 198 | (7%) | 167 | (6%) |
| Nausea & Vomiting | 68 | (2%) | 60 | (2%) |
| Diarrhea | 52 | (2%) | 56 | (2%) |
| Gastrointestinal Discomfort & Pain | 19 | (<1%) | 12 | (<1%) |
| Gastrointestinal Signs & Symptoms | 12 | (<1%) | 12 | (<1%) |
| Dental Discomfort & Pain | 11 | (<1%) | 5 | (<1%) |
| Dyspeptic Symptoms | 8 | (<1%) | 6 | (<1%) |
| Gastroenteritis | 7 | (<1%) | 6 | (<1%) |
| Abdominal Discomfort & Pain | 6 | (<1%) | 7 | (<1%) |
| Viral Gastrointestinal Infections | 8 | (<1%) | 4 | (<1%) |
| Oral Ulcerations | 8 | (<1%) | 3 | (<1%) |
| Constipation | 7 | (<1%) | 4 | (<1%) |
| Hyposalivation | 7 | (<1%) | 2 | (<1%) |
| Gastrointestinal Gaseous Symptoms | 3 | (<1%) | 5 | (<1%) |
| Regurgitation & Reflux | 3 | (<1%) | 4 | (<1%) |
| Gastrointestinal Infections | 6 | (<1%) | 0 | |
| Gastrointestinal Polyps Of Uncertain Behavior | 3 | (<1%) | 0 | |
| Salivary Gland Inflammation | 2 | (<1%) | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| GASTROINTESTINAL (continued) | | | | |
| Any event | 198 | (7%) | 167 | (6%) |
| Gastrointestinal Herniae | 1 | (<1%) | 2 | (<1%) |
| Abdominal Distention | 0 | | 3 | (<1%) |
| Fungal Gastrointestinal Infections | 2 | (<1%) | 0 | |
| Dental Operations | 1 | (<1%) | 1 | (<1%) |
| Esophagitis | 1 | (<1%) | 1 | (<1%) |
| Gastrointestinal Obstructions | 1 | (<1%) | 1 | (<1%) |
| Hemorrhoids | 1 | (<1%) | 1 | (<1%) |
| Irritable Bowel Syndrome | 0 | | 2 | (<1%) |
| Mouth & Tongue Disorders | 0 | | 2 | (<1%) |
| Oral Burning | 0 | | 2 | (<1%) |
| Dental & Gum Inflammation | 1 | (<1%) | 0 | |
| Dentures | 1 | (<1%) | 0 | |
| Disorders Of Tooth Development | 1 | (<1%) | 0 | |
| Gastric Ulcers | 1 | (<1%) | 0 | |
| Oral Discomfort & Pain | 1 | (<1%) | 0 | |
| Oral Lesions | 1 | (<1%) | 0 | |
| Oral Swelling | 1 | (<1%) | 0 | |
| Salivary Gland Swelling | 1 | (<1%) | 0 | |
| Disorders Of Hard Tissues Of Teeth | 0 | | 1 | (<1%) |
| Gastritis | 0 | | 1 | (<1%) |
| Gastrointestinal Hemorrhage | 0 | | 1 | (<1%) |
| Gastrointestinal Procedures | 0 | | 1 | (<1%) |
| Gum Signs & Symptoms | 0 | | 1 | (<1%) |
| Oral Erythema & Rashes | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| HEPATOBILIARY TRACT & PANCREAS : | | | | |
| Any event | 1 | (<1%) | 1 | (<1%) |
| Hepatobiliary Signs | 1 | (<1%) | 0 | |
| Gallbladder Disorders | 0 | | 1 | (<1%) |
| LOWER RESPIRATORY : | | | | |
| Any event | 724 | (25%) | 604 | (20%) |
| Cough | 446 | (15%) | 397 | (13%) |
| Viral Respiratory Infections | 264 | (9%) | 194 | (7%) |
| Bronchitis | 29 | (<1%) | 32 | (1%) |
| Asthma | 27 | (<1%) | 21 | (<1%) |
| Breathing Disorders | 19 | (<1%) | 8 | (<1%) |
| Sputum | 12 | (<1%) | 12 | (<1%) |
| Lower Respiratory Signs & Symptoms | 3 | (<1%) | 11 | (<1%) |
| Chest Sounds | 6 | (<1%) | 2 | (<1%) |
| Airways Constriction & Obstruction | 4 | (<1%) | 3 | (<1%) |
| Chronic Obstructive Airways Disease | 5 | (<1%) | 1 | (<1%) |
| Pneumonia | 5 | (<1%) | 1 | (<1%) |
| Lower Respiratory Infections | 3 | (<1%) | 1 | (<1%) |
| Bacterial Respiratory Infections | 2 | (<1%) | 0 | |
| Allergic Lower Respiratory Disorders | 1 | (<1%) | 0 | |
| Lower Respiratory Failure | 1 | (<1%) | 0 | |
| Lung Disorders | 0 | | 1 | (<1%) |
| Pleuritis | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| MUSCULOSKELETAL : | | | | |
| Any event | 328 | (11%) | 349 | (12%) |
| Muscle Pain | 176 | (6%) | 192 | (6%) |
| Musculoskeletal Pain | 126 | (4%) | 123 | (4%) |
| Arthralgia & Articular Rheumatism | 17 | (<1%) | 38 | (1%) |
| Muscle Cramps & Spasms | 7 | (<1%) | 5 | (<1%) |
| Musculoskeletal Inflammation | 6 | (<1%) | 6 | (<1%) |
| Arthritis | 5 | (<1%) | 5 | (<1%) |
| Muscle Stiffness Tightness & Rigidity | 5 | (<1%) | 2 | (<1%) |
| Bone & Cartilage Disorders | 2 | (<1%) | 4 | (<1%) |
| Degenerative Arthritis | 2 | (<1%) | 2 | (<1%) |
| Spinal Arthritis | 2 | (<1%) | 0 | |
| Acquired Musculoskeletal Deformities | 1 | (<1%) | 0 | |
| Muscle Discomfort | 1 | (<1%) | 0 | |
| Synovium Tendon Fascia & Bursa Disorders | 1 | (<1%) | 0 | |
| Bone & Skeletal Pain | 0 | | 1 | (<1%) |
| Joint Edema Swelling & Effusion | 0 | | 1 | (<1%) |
| Joint Stiffness Tightness & Rigidity | 0 | | 1 | (<1%) |
| NEUROLOGY : | | | | |
| Any event | 657 | (22%) | 632 | (21%) |
| Headaches | 614 | (21%) | 602 | (20%) |
| Dizziness | 15 | (<1%) | 15 | (<1%) |
| Migraines | 13 | (<1%) | 13 | (<1%) |
| Sleep Disorders | 10 | (<1%) | 11 | (<1%) |
| Compressed Nerve Syndromes | 5 | (<1%) | 1 | (<1%) |
| Disorders Of Equilibrium | 3 | (<1%) | 3 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| NEUROLOGY (continued) | | | | |
| Any event | 657 | (22%) | 632 | (21%) |
| Vertigo | 3 | (<1%) | 3 | (<1%) |
| Tremors | 2 | (<1%) | 3 | (<1%) |
| Confusion | 2 | (<1%) | 1 | (<1%) |
| Disturbances Of Sense Of Taste | 2 | (<1%) | 0 | |
| Hypoesthesia | 1 | (<1%) | 1 | (<1%) |
| Paresthesia | 1 | (<1%) | 1 | (<1%) |
| Convulsions | 1 | (<1%) | 0 | |
| Hypnagogic Effects | 1 | (<1%) | 0 | |
| Muscle Twitching & Fasciculation | 1 | (<1%) | 0 | |
| Parkinsonism | 1 | (<1%) | 0 | |
| Tics | 1 | (<1%) | 0 | |
| Neuritis | 0 | | 1 | (<1%) |
| NON-SITE SPECIFIC : | | | | |
| Any event | 384 | (13%) | 407 | (14%) |
| Temperature Regulation Disturbances | 228 | (8%) | 220 | (7%) |
| Malaise & Fatigue | 182 | (6%) | 200 | (7%) |
| Pain | 20 | (<1%) | 18 | (<1%) |
| Chest Symptoms | 17 | (<1%) | 19 | (<1%) |
| Non-Specific Conditions | 17 | (<1%) | 7 | (<1%) |
| Viral Infections | 13 | (<1%) | 9 | (<1%) |
| Allergies & Allergic Reactions | 9 | (<1%) | 11 | (<1%) |
| Edema & Swelling | 5 | (<1%) | 5 | (<1%) |
| Infections | 3 | (<1%) | 4 | (<1%) |
| Fungal Infections | 3 | (<1%) | 2 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| NON-SITE SPECIFIC (continued) | | | | |
| Any event | 384 | (13%) | 407 | (14%) |
| Cramps | 0 | | 3 | (<1%) |
| Bacterial Infections | 1 | (<1%) | 1 | (<1%) |
| Cysts Lumps & Masses | 1 | (<1%) | 1 | (<1%) |
| Odors & Taste | 1 | (<1%) | 1 | (<1%) |
| Allergic Reaction To Animals | 0 | | 2 | (<1%) |
| Allergic Reaction To Medicinal Substances | 1 | (<1%) | 0 | |
| Allergic Reaction To Non-Drug Products | 1 | (<1%) | 0 | |
| Inflammation | 1 | (<1%) | 0 | |
| Benign Neoplasia | 0 | | 1 | (<1%) |
| Collagen Vascular Diseases | 0 | | 1 | (<1%) |
| Discomfort | 0 | | 1 | (<1%) |
| General Signs & Symptoms | 0 | | 1 | (<1%) |
| PSYCHIATRY : | | | | |
| Any event | 10 | (<1%) | 11 | (<1%) |
| Anxiety | 2 | (<1%) | 3 | (<1%) |
| Agitation | 4 | (<1%) | 0 | |
| Depressive Disorders | 2 | (<1%) | 2 | (<1%) |
| Situational Disorders | 1 | (<1%) | 1 | (<1%) |
| Intoxication & Hangover | 0 | | 2 | (<1%) |
| Mood Disorders | 0 | | 2 | (<1%) |
| Depressive Moods | 1 | (<1%) | 0 | |
| Mood Elevations | 1 | (<1%) | 0 | |
| Bipolar Disorders | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| REPRODUCTION : | | | | |
| Any event | 51 | (2%) | 39 | (1%) |
| Menstruation Symptoms | 30 | (1%) | 30 | (1%) |
| Fungal Reproductive Infections | 8 | (<1%) | 4 | (<1%) |
| Inflammation Of Prostate | 2 | (<1%) | 1 | (<1%) |
| Menopause & Post Menopausal State | 2 | (<1%) | 0 | |
| Reproductive Infections | 2 | (<1%) | 0 | |
| Female Reproductive Tract Bleeding & Hemorrhage | 1 | (<1%) | 1 | (<1%) |
| Primary Malignant Breast Neoplasia | 1 | (<1%) | 1 | (<1%) |
| Bacterial Reproductive Infections | 1 | (<1%) | 0 | |
| Cysts Lumps & Masses Of Female Reproductive Tract | 1 | (<1%) | 0 | |
| Menstrual Disorders | 1 | (<1%) | 0 | |
| Nipple Symptoms | 1 | (<1%) | 0 | |
| Polyps Of Female Reproductive Tract | 1 | (<1%) | 0 | |
| Inflammation Of Epididymis | 0 | | 1 | (<1%) |
| Inflammation Of Vagina | 0 | | 1 | (<1%) |
| SKIN : | | | | |
| Any event | 49 | (2%) | 55 | (2%) |
| Skin Rashes | 9 | (<1%) | 12 | (<1%) |
| Viral Skin Infections | 9 | (<1%) | 4 | (<1%) |
| Pruritus | 6 | (<1%) | 7 | (<1%) |
| Skin Infections | 4 | (<1%) | 4 | (<1%) |
| Sweating | 2 | (<1%) | 6 | (<1%) |
| Urticaria | 3 | (<1%) | 2 | (<1%) |
| Acne & Folliculitis | 3 | (<1%) | 1 | (<1%) |
| Primary Malignant Skin Neoplasia | 3 | (<1%) | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| SKIN (continued) | | | | |
| Any event | 49 | (2%) | 55 | (2%) |
| Fungal Skin Infections | 2 | (<1%) | 2 | (<1%) |
| Skin & Subcutaneous Operations | 1 | (<1%) | 3 | (<1%) |
| Eczema | 1 | (<1%) | 2 | (<1%) |
| Dermatitis & Dermatosis | 0 | | 3 | (<1%) |
| Erythematous Skin Conditions | 0 | | 3 | (<1%) |
| Allergic Skin Reactions | 1 | (<1%) | 1 | (<1%) |
| Skin Irritation | 1 | (<1%) | 1 | (<1%) |
| Skin Lesions | 1 | (<1%) | 1 | (<1%) |
| Nail Disorders | 0 | | 2 | (<1%) |
| Erythematous Skin Rashes | 1 | (<1%) | 0 | |
| Pruritic Skin Rashes | 1 | (<1%) | 0 | |
| Skin Erythema | 1 | (<1%) | 0 | |
| Skin Fissures & Cracks | 1 | (<1%) | 0 | |
| Bullous Skin Rashes | 0 | | 1 | (<1%) |
| Disorders Of Sweat & Sebum | 0 | | 1 | (<1%) |
| Skin Erosions & Ulcers | 0 | | 1 | (<1%) |
| Skin Hemorrhage | 0 | | 1 | (<1%) |
| UROLOGY : | | | | |
| Any event | 16 | (<1%) | 14 | (<1%) |
| Urinary Infections | 5 | (<1%) | 8 | (<1%) |
| Bladder Inflammation | 2 | (<1%) | 2 | (<1%) |
| Urinary Calculi | 2 | (<1%) | 2 | (<1%) |
| Urinary Tract Hemorrhage | 2 | (<1%) | 1 | (<1%) |
| Urinary Frequency | 2 | (<1%) | 0 | |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004

Protocol: NAIA3005, NAI30010, NAI30031 & NAI30034
Population: Safety

Table 8.56
Summary of All Adverse Events

During Prophylaxis: Non-Smokers

| BODY SYSTEM<br>Event | Placebo (N=2945) | | Zanamivir (N=2955) | |
|---|---|---|---|---|
| ANY EVENT | 1604 | (54%) | 1531 | (52%) |
| UROLOGY (continued) | | | | |
| Any event | 16 | (<1%) | 14 | (<1%) |
| Abnormal Urine Test Results | 1 | (<1%) | 0 | |
| Nocturia | 1 | (<1%) | 0 | |
| Pyelitis | 1 | (<1%) | 0 | |
| Renal Impairment | 1 | (<1%) | 0 | |
| Abnormal Urine Odor | 0 | | 1 | (<1%) |
| Renal Signs & Symptoms | 0 | | 1 | (<1%) |

Data for NAI30010 and NAI30031 includes contact cases only
Patient smoking status was not available for NAIA3003 and NAIA3004